RESUMO
There is a need for molecular markers that predict biological behavior of adult soft tissue tumors. Elevated levels of osteopontin (OPN) a transformation-linked protein, have been associated with poor survival in many cancers. OPN induces cell migration in cancer cells, in part through activation of the hepatocyte growth factor (HGF) receptor (Met) and its signaling pathway. Met expression has been associated with a poor prognosis in some sarcomas. In a series of 15 patients with adult soft tissue tumors, we found that mRNA levels of OPN (p=0.015), Met (p=0.03) and HGF (p<0.001) were significantly higher in tumor tissues relative to paired normal tissues. By immunohistochemistry, in tumor tissue from 33 patients, we demonstrated that increased expression of OPN, but not Met protein, was associated with higher stage (p=0.025) and grade (p=0.005). We found that increased expression of OPN, but not Met protein, was associated with decreased overall survival (p=0.008) at five years. This study, which is the first to examine coexpression of these two markers, suggests that OPN may have potential as a prognostic marker in adult soft tissue sarcomas, and further that OPN+/-Met signaling pathways may contribute to their biological behavior.
Assuntos
Expressão Gênica , Fator de Crescimento de Hepatócito/metabolismo , Proteínas Proto-Oncogênicas c-met/metabolismo , Sialoglicoproteínas/metabolismo , Neoplasias de Tecidos Moles/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Fator de Crescimento de Hepatócito/genética , Humanos , Masculino , Pessoa de Meia-Idade , Osteopontina , Proteínas Proto-Oncogênicas c-met/genética , Sialoglicoproteínas/genética , Neoplasias de Tecidos Moles/patologiaRESUMO
PURPOSE: Many patients with non-small cell lung cancer (NSCLC) are eligible only for palliative radiation (RT) at presentation. This study was designed to assess the feasibility of adding the anti-EGFR monoclonal antibody nimotuzumab to palliative thoracic RT. METHODS: Patients with stage IIB, III or IV NSCLC considered unsuitable for radical radiation or chemo-radiation received nimotuzumab weekly 8× (100, 200 or 400 mg) with radiation (30 or 36 Gy in 3 Gy fractions). If response or disease stability was observed, nimotuzumab was continued every other week starting from week 10 until progression or toxicity. RESULTS: Eighteen patients were enrolled: 6 at 100 mg, 7 at 200 mg, 5 at 400 mg nimotuzumab. Patient characteristics included median age 69 years, 11 males, 17 smokers, 17 Caucasians, stage IIIA/IIIB/IV 2/7/9, 5 Eastern Cooperative Oncology Group performance status (PS) 2; 9 adenocarcinoma. The most commonly reported adverse events were fatigue, anorexia, chills, pain and hypophosphatemia (grades 1 to 2 in most patients). No severe skin or allergic toxicity was noted. No dose-limiting toxicity was encountered. Objective response rate and disease control rate inside the radiation field were 66 and 94.0%, respectively. CONCLUSION: Nimotuzumab administered concurrently with palliative thoracic radiation is well tolerated at each of the three doses investigated in NSCLC patients unsuitable for radical treatment. The low toxicity and absence of rash make this combination therapeutically attractive for frail patients with other co-morbidities and poor performance status. These results support further testing of this regimen in the phase II setting.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Humanizados , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Canadá , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Terapia Combinada , Relação Dose-Resposta a Droga , Receptores ErbB/antagonistas & inibidores , Feminino , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/radioterapia , Masculino , Estadiamento de Neoplasias , Cuidados Paliativos/métodos , Doses de RadiaçãoRESUMO
Investigation of the regulation of cell growth, differentiation and death by signalling pathways has led to a greater understanding of how alterations in these pathways play a critical role in the development of some cancers, and has opened new opportunities for their treatment. In the present review, results with the prototype drug of this class, imatinib (Gleevec, Glivec [formerly STI571]; Novartis, Switzerland), in metastatic gastrointestinal stromal tumours are presented. The present review originated from a conference of the authors held in Montreal, Quebec in June 2003, under the sponsorship of Novartis.